MRK Relative Valuation - Merck KGaA

Watchlist Manager

Watchlist

Price: 107.8 EUR -2.13% Market Closed

Market Cap: €46.9B

Relative Value

The Relative Value of one MRK stock under the Base Case scenario is hidden EUR. Compared to the current market price of 107.8 EUR, Merck KGaA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

What is Relative Valuation?

How is Relative Value calculated?

MRK Relative Value

Show

Worst Case

Base Case

Best Case

Valuation Multiples

View Details

Multiples Across Competitors

All Multiples

P/S

P/E

EV/EBITDA

EV/EBIT

Forward Multiples

			Market Cap	P/S	P/E	EV/EBITDA	EV/EBIT
DE		Merck KGaA XETRA:MRK	47B EUR	2.2	18	8.3	12.8
US		Eli Lilly and Co NYSE:LLY	952.7B USD	14.6	46.2	31.1	33.2
US		Johnson & Johnson NYSE:JNJ	584.1B USD	6.2	21.8	15.1	18.6
CH		Roche Holding AG SIX:ROG	262.5B CHF	4.3	20.5	12.1	13.6
CH		Novartis AG SIX:NOVN	238.2B CHF	5.3	21.5	13.3	17.1
UK		AstraZeneca PLC LSE:AZN	223.5B GBP	5.1	29.3	16.2	22.9
US		Merck & Co Inc NYSE:MRK	289.8B USD	4.5	15.9	9.9	12
IE	E	Endo International PLC LSE:0Y5F	218B USD	94	-74.6	344.9	865
DK		Novo Nordisk A/S CSE:NOVO B	1.1T DKK	3.7	11.1	8.2	9.6
US		Pfizer Inc NYSE:PFE	152.4B USD	2.4	19.6	7.6	10.1
US		Bristol-Myers Squibb Co NYSE:BMY	122B USD	2.5	17.3	7.3	9

				Revenue Growth	P/S to Growth
DE		Merck KGaA XETRA:MRK	Average P/S: 13.2 2.2	4%	0.6
US		Eli Lilly and Co NYSE:LLY	14.6	19%	0.8
US		Johnson & Johnson NYSE:JNJ	6.2	6%	1
CH		Roche Holding AG SIX:ROG	4.3	4%	1.1
CH		Novartis AG SIX:NOVN	5.3	5%	1.1
UK		AstraZeneca PLC LSE:AZN	5.1	7%	0.7
US		Merck & Co Inc NYSE:MRK	4.5	5%	0.9
IE	E	Endo International PLC LSE:0Y5F	94	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	3.7	2%	1.8
US		Pfizer Inc NYSE:PFE	2.4	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	2.5	-5%	N/A

				Earnings Growth	PEG
DE		Merck KGaA XETRA:MRK	Average P/E: 22.1 18	18%	1
US		Eli Lilly and Co NYSE:LLY	46.2	32%	1.4
US		Johnson & Johnson NYSE:JNJ	21.8	7%	3.1
CH		Roche Holding AG SIX:ROG	20.5	14%	1.5
CH		Novartis AG SIX:NOVN	21.5	14%	1.5
UK		AstraZeneca PLC LSE:AZN	29.3	26%	1.1
US		Merck & Co Inc NYSE:MRK	15.9	14%	1.1
IE	E	Endo International PLC LSE:0Y5F	Negative Multiple: -74.6	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	11.1	1%	11.1
US		Pfizer Inc NYSE:PFE	19.6	22%	0.9
US		Bristol-Myers Squibb Co NYSE:BMY	17.3	16%	1.1

				EBITDA Growth	EV/EBITDA to Growth
DE		Merck KGaA XETRA:MRK	Average EV/EBITDA: 43.1 8.3	2%	4.1
US		Eli Lilly and Co NYSE:LLY	31.1	22%	1.4
US		Johnson & Johnson NYSE:JNJ	15.1	2%	7.6
CH		Roche Holding AG SIX:ROG	12.1	6%	2
CH		Novartis AG SIX:NOVN	13.3	5%	2.7
UK		AstraZeneca PLC LSE:AZN	16.2	13%	1.2
US		Merck & Co Inc NYSE:MRK	9.9	3%	3.3
IE	E	Endo International PLC LSE:0Y5F	344.9	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	8.2	1%	8.2
US		Pfizer Inc NYSE:PFE	7.6	-9%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	7.3	-10%	N/A

				EBIT Growth	EV/EBIT to Growth
DE		Merck KGaA XETRA:MRK	Average EV/EBIT: 93.1 12.8	4%	3.2
US		Eli Lilly and Co NYSE:LLY	33.2	22%	1.5
US		Johnson & Johnson NYSE:JNJ	18.6	7%	2.7
CH		Roche Holding AG SIX:ROG	13.6	5%	2.7
CH		Novartis AG SIX:NOVN	17.1	9%	1.9
UK		AstraZeneca PLC LSE:AZN	22.9	21%	1.1
US		Merck & Co Inc NYSE:MRK	12	6%	2
IE	E	Endo International PLC LSE:0Y5F	865	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	9.6	3%	3.2
US		Pfizer Inc NYSE:PFE	10.1	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	9	-7%	N/A

Merck KGaA
XETRA:MRK

Relative Value

Valuation Multiples

Multiples Across Competitors

MRK Competitors Multiples
Merck KGaA Competitors

See Also

Company

Help

Tools

Stocks

Merck KGaA XETRA:MRK

Relative Value

Valuation Multiples

Multiples Across Competitors

MRK Competitors Multiples Merck KGaA Competitors

See Also

Company

Help

Tools

Stocks

Merck KGaA
XETRA:MRK

MRK Competitors Multiples
Merck KGaA Competitors